Clinical trials
for patients

The objective of this trial is to determine how well a new investigational drug called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib.

The objective of this study is to collect data on the safety of the investigational study medication and to determine how well it works in treating grass pollen allergy.

The primary objective is to evaluate the safety and tolerability of the study drug.

This is the first time ODM-216 is being tested in humans. ODM-216 is a type of immunotherapy. It works by helping the immune system better recognize and respond to cancer. The primary objective of this study is to determine the safety and tolerability of ODM-216 and establish the optimal dose.

The purpose of the study is to evaluate progression-free survival (PFS) with casdatifan versus placebo, when both are administered in combination with cabozantinib, in adult patients with confirmed advanced or metastatic clear cell renal cell carcinoma who experienced disease progression during or after prior anti-PD-1 or anti-PD-L1 immunotherapy.

The purpose of this study is to test several combinations of new investigational drugs (study drugs), with chemotherapy (if you have not yet received treatment for your cancer) or without chemotherapy (if you have already received treatment for your cancer). If you have previously received treatment for colorectal cancer, you may receive the study drug or drugs together with cetuximab.

The primary objective is to evaluate the efficacy of telisotuzumab adizutecan combinations compared with standard treatment in metastatic colorectal cancer (mCRC).

The primary objective of this study is to evaluate the efficacy of the study drug repotrectinib (a kinase inhibitor that blocks the activity of the abnormal ROS1 protein) in patients with NSCLC who have a ROS1 alteration and active brain metastases.

The primary objective is to determine whether proactive neoadjuvant systemic treatment (FOLFOX), with or without HIPEC with mitomycin C, followed by postoperative adjuvant systemic treatment, increases 36-month disease-free survival in patients with locally advanced colon cancer compared with standard treatment.

The primary objective of Part B is to further evaluate the safety of the study drug and how well it is tolerated by the body in a larger number of people with myasthenia gravis (MG). The study will also assess whether the study drug is effective in people with generalized myasthenia gravis (gMG) and ocular myasthenia gravis (oMG).

The purpose of this trial is to test an investigational drug called daraxonrasib (RMC-6236). Daraxonrasib is an investigational drug, which means that it has not been approved by the Spanish Agency for Medicines and Health Products (AEMPS) or by any other health authority in any country. Daraxonrasib is currently being investigated in other ongoing studies in pancreatic cancer, and its safety, tolerability, and efficacy are being evaluated in comparison with usual clinical practice.

The purpose of this clinical study is to determine whether obrixtamig in combination with atezolizumab, carboplatin, and etoposide (standard chemotherapy) is more effective than standard chemotherapy alone in treating people with advanced small cell lung cancer.

The main objectives of the study are as follows: Part A (Phase 1, safety run-in, dose escalation): To determine whether BNT314 in combination with pumitamig can be administered safely without causing serious side effects in participants. Part B (Phase 1, dose optimization): To assess whether BNT314 in combination with pumitamig and standard chemotherapy is safe for participants and to determine the appropriate dose of BNT314 to be used in Part C. Part C (Phase 2, randomization versus standard tr...

The purpose of this study is to compare the effects, both beneficial and adverse, of cevostamab in combination with pomalidomide and dexamethasone with the standard treatment selected by the study physician—daratumumab in combination with pomalidomide and dexamethasone (DPd), elotuzumab in combination with pomalidomide and dexamethasone (EPd), or carfilzomib in combination with dexamethasone (Kd)—in people with multiple myeloma.

The purpose of this study is to help researchers understand whether JNJ-95804306 is safe and effective for treating people with acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS, also known as myelodysplastic syndrome), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL). The study aims to determine a dose—the amount of medication taken at one time—of JNJ-95804306 that can safely and effectively treat AML, MDS, CLL, and SLL. It will also assess the sid...

The main objective of this study is to evaluate the safety and tolerability of EGL-001 in participants with selected advanced and/or metastatic solid tumors whose disease has progressed after previously deriving benefit from standard-of-care treatment with an immune checkpoint inhibitor.

The primary objective of this trial is to determine whether RO7589831 administered at different doses has effects, whether positive or negative, as well as what happens to RO7589831 once it enters the body and how it acts in the body and on your disease.

The objective of this study is to determine what dose of the study drug, called “CABA-201,” can be safely administered to patients with idiopathic inflammatory myopathy (IIM) and juvenile idiopathic inflammatory myopathy (JIIM) or myositis. Although the cause is not well understood, JIIM and some subtypes of IIM, including dermatomyositis (DM), antisynthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), are believed to involve B cells, which cause the body to attack differen...